Therapy Areas: Cardiovascular
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
6 May 2025 - Fangzhou Inc (HK:06086), a Chinese online chronic disease management platform, announced on Monday the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibi...
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
5 May 2025 - Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) announced on Friday that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submi...
Avacta Therapeutics reports positive Phase 1 data for lead candidate
28 April 2025 -

Life sciences company Avacta Therapeutics (AIM: AVCT) announced on Monday that it presented compelling Phase 1 clinical data for its...

Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
28 April 2025 - Innovent Biologics Inc (HKEX:01801), a China-based biopharmaceutical company that develops, manufactures and commercialises medicines for the treatment of oncologic, autoimmune, cardio...
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
25 April 2025 - Primo Biotechnology Co, Ltd, a Taiwan-based radiopharmaceutical company, announced on Thursday that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Foo...
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment
25 April 2025 - Renibus Therapeutics, a US-based clinical late-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, on Thursday announced...